PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.

Affiliation auteurs!!!! Error affiliation !!!!
TitrePROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.
Type de publicationJournal Article
Year of Publication2017
AuteursDe Bono JS, Hussain M, Thiery-Vuillemin A, Mateo J, A. Sartor O, Chi KN, Fizazi K, Twardowski P, Agarwal N, Sandhu SKaur, Olmos D, Shore ND, Saad F, Liu S, Goessl CDietrich, Burgents J
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume35
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2017.35.15_suppl.TPS5091